Nasal immunization studies by cationic, fusogenic and cationic-fusogenic liposomes encapsulated with tetanus toxoid.
Particulate antigens are more effective than soluble antigens in induction of systemic and mucosal immunity; possibly because they are more efficiently endocytosed by mucosal-associated lymphoid tissue (MALT) M cells. In this study, we determined the systemic and mucosal immune responses in rabbits following intranasal immunization with tetanus toxoid (TT) entrapped in cationic, fusogenic and cationic-fusogenic liposomes. Liposomes containing TT were prepared by dehydration-rehydration method. The volume mean diameter of cationic, fusogenic and cationic-fusogenic liposomes were 3.4 +/- 0.6, 4.3 +/- 2.3 and 3.4 +/- 1.5 microm, respectively. Encapsulation efficiency of TT in cationic, fusogenic and cationic-fusogenic liposomes was respectively determined as 49.1 +/- 8.4%, 48.5 +/- 2.1% and 50.8 +/- 4.9%. After 3 months, the leaking of encapsulated TT from liposomes ranged between 2.02 - 5.46%. Immunoreactivities of encapsulated TT in all kinds of liposomes were completely preserved, as studied by Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Enzyme-Linked Immunosorbent Assay (ELISA). The highest serum immunoglobulin G (IgG) and antitoxin titers were observed in groups immunized with solution formulation (P< 0.001). However, the highest mucosal secretory IgA (sIgA) titers were achieved by fusogenic liposomes (five times more titers compared with TT solution, and 15 times more titers compared with i.m. vaccine), followed by cationic-fusogenic liposomes. No hemolysis was occurred on incubation of liposomes and human erythrocytes. Also after nasal administration of plain liposomes to human volunteers, no local irritation was seen. This study suggests that intranasal administration of fusogenic and cationic-fusogenic liposomes encapsulated with vaccines could be an effective way for inducing mucosal immune responses.
Tafaghodi
M
M
School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. tafaghodim@mums.ac.ir
Jaafari
M R
MR
Tabassi
S A Sajadi
SA
D000281:Administration, Intranasal; D000818:Animals; D000917:Antibody Formation; D002412:Cations; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry*; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D007114:Immunization / Q000379:methods*; D007070:Immunoglobulin A / Q000378:metabolism; D007074:Immunoglobulin G / Q000097:blood; D008081:Liposomes; D008561:Membrane Fusion; D010316:Particle Size; D011817:Rabbits; D013743:Tetanus Antitoxin / Q000097:blood; D013745:Tetanus Toxoid / Q000008:administration & dosage* / Q000276:immunology
D002412:Cations; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D008081:Liposomes; D013743:Tetanus Antitoxin; D013745:Tetanus Toxoid